EGFR Inhibitors in Cancer Treatment
EGFR inhibitors target a key protein that drives the growth of many cancer cells. These drugs block signals that tell cells to divide and survive. As a result, they slow tumour growth in selected patients. However, doctors use them only after testing for specific genetic changes.
EGFR stands for epidermal growth factor receptor. It sits on the surface of cells and responds to growth signals. In some cancers, mutations or extra copies of EGFR keep the signal active all the time. Therefore, cancer cells grow faster than normal cells. Non-small cell lung cancer, colorectal cancer, and certain head and neck cancers often show these changes.
EGFR inhibitors fall into two main groups. Small-molecule tyrosine kinase inhibitors enter the cell and block the enzyme inside the receptor. Monoclonal antibodies bind to the outside of the receptor and prevent it from receiving signals. Additionally, both types interrupt the same pathway that promotes uncontrolled growth.
Doctors select patients through genetic tests. They look for EGFR mutations in tumour samples. Patients with these mutations often respond better to the drugs than patients without them. Moreover, newer inhibitors can overcome some resistance mutations that appear later. As a result, treatment can continue even after the cancer adapts.
These drugs improve outcomes in the right patients. They can shrink tumours and delay disease progression. Furthermore, they often cause fewer severe side effects than traditional chemotherapy. Common side effects include skin rash and diarrhoea. However, most patients manage these effects with supportive care.
Resistance remains a major challenge. Cancer cells can develop new mutations that bypass the blocked pathway. Therefore, researchers develop next-generation inhibitors that target these changes. Combination approaches with other drugs also help delay resistance in some cases.
Overall, EGFR inhibitors represent an important advance in precision cancer treatment. They match therapy to the biology of each tumour. Continued research aims to widen their use and overcome resistance so more patients can benefit.